208 related articles for article (PubMed ID: 27380031)
1. Strategies towards in vivo imaging of active transglutaminase type 2 using positron emission tomography.
van der Wildt B; Lammertsma AA; Drukarch B; Windhorst AD
Amino Acids; 2017 Mar; 49(3):585-595. PubMed ID: 27380031
[TBL] [Abstract][Full Text] [Related]
2. Development of carbon-11 labeled acryl amides for selective PET imaging of active tissue transglutaminase.
van der Wildt B; Wilhelmus MM; Bijkerk J; Haveman LY; Kooijman EJ; Schuit RC; Bol JG; Jongenelen CA; Lammertsma AA; Drukarch B; Windhorst AD
Nucl Med Biol; 2016 Apr; 43(4):232-42. PubMed ID: 27067043
[TBL] [Abstract][Full Text] [Related]
3. Development of fluorine-18 labeled peptidic PET tracers for imaging active tissue transglutaminase.
van der Wildt B; Wilhelmus MM; Kooijman EJ; Jongenelen CA; Schuit RC; Büchold C; Pasternack R; Lammertsma AA; Drukarch B; Windhorst AD
Nucl Med Biol; 2017 Jan; 44():90-104. PubMed ID: 27837727
[TBL] [Abstract][Full Text] [Related]
4. An unprecedented dual antagonist and agonist of human Transglutaminase 2.
Yi MC; Palanski BA; Quintero SA; Plugis NM; Khosla C
Bioorg Med Chem Lett; 2015 Nov; 25(21):4922-4926. PubMed ID: 26004580
[TBL] [Abstract][Full Text] [Related]
5. Structure of natural variant transglutaminase 2 reveals molecular basis of gaining stability and higher activity.
Ha HJ; Kwon S; Jeong EM; Kim CM; Lee KB; Kim IG; Park HH
PLoS One; 2018; 13(10):e0204707. PubMed ID: 30321187
[TBL] [Abstract][Full Text] [Related]
6. Transglutaminase 2 undergoes a large conformational change upon activation.
Pinkas DM; Strop P; Brunger AT; Khosla C
PLoS Biol; 2007 Dec; 5(12):e327. PubMed ID: 18092889
[TBL] [Abstract][Full Text] [Related]
7. Transglutaminase 2 strongly binds to an extracellular matrix component other than fibronectin via its second C-terminal beta-barrel domain.
Stamnaes J; Cardoso I; Iversen R; Sollid LM
FEBS J; 2016 Nov; 283(21):3994-4010. PubMed ID: 27685605
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the interaction between transglutaminase 2 and fibronectin.
Cardoso I; Østerlund EC; Stamnaes J; Iversen R; Andersen JT; Jørgensen TJ; Sollid LM
Amino Acids; 2017 Mar; 49(3):489-500. PubMed ID: 27394141
[TBL] [Abstract][Full Text] [Related]
9. Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2.
Klöck C; Jin X; Choi K; Khosla C; Madrid PB; Spencer A; Raimundo BC; Boardman P; Lanza G; Griffin JH
Bioorg Med Chem Lett; 2011 May; 21(9):2692-6. PubMed ID: 21215619
[TBL] [Abstract][Full Text] [Related]
10. Transglutaminase as a therapeutic target for celiac disease.
Sulic AM; Kurppa K; Rauhavirta T; Kaukinen K; Lindfors K
Expert Opin Ther Targets; 2015 Mar; 19(3):335-48. PubMed ID: 25410283
[TBL] [Abstract][Full Text] [Related]
11. Dihydroisoxazole analogs for labeling and visualization of catalytically active transglutaminase 2.
Dafik L; Khosla C
Chem Biol; 2011 Jan; 18(1):58-66. PubMed ID: 21276939
[TBL] [Abstract][Full Text] [Related]
12. Thioredoxin-1 Selectively Activates Transglutaminase 2 in the Extracellular Matrix of the Small Intestine: IMPLICATIONS FOR CELIAC DISEASE.
Plugis NM; Palanski BA; Weng CH; Albertelli M; Khosla C
J Biol Chem; 2017 Feb; 292(5):2000-2008. PubMed ID: 28003361
[TBL] [Abstract][Full Text] [Related]
13. Detection and identification of potential transglutaminase 2 substrates in the mouse renal glomeruli.
Ito Y; Tatsukawa H; Yamaguchi H; Takahashi K; Hitomi K; Yuzawa Y
Arch Biochem Biophys; 2018 Dec; 660():11-19. PubMed ID: 30300608
[TBL] [Abstract][Full Text] [Related]
14. Unexpected role of surface transglutaminase type II in celiac disease.
Maiuri L; Ciacci C; Ricciardelli I; Vacca L; Raia V; Rispo A; Griffin M; Issekutz T; Quaratino S; Londei M
Gastroenterology; 2005 Nov; 129(5):1400-13. PubMed ID: 16285941
[TBL] [Abstract][Full Text] [Related]
15. Enhanced B-Cell Receptor Recognition of the Autoantigen Transglutaminase 2 by Efficient Catalytic Self-Multimerization.
Stamnaes J; Iversen R; du Pré MF; Chen X; Sollid LM
PLoS One; 2015; 10(8):e0134922. PubMed ID: 26244572
[TBL] [Abstract][Full Text] [Related]
16. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
[TBL] [Abstract][Full Text] [Related]
17. Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.
Kerr C; Szmacinski H; Fisher ML; Nance B; Lakowicz JR; Akbar A; Keillor JW; Lok Wong T; Godoy-Ruiz R; Toth EA; Weber DJ; Eckert RL
Oncogene; 2017 May; 36(21):2981-2990. PubMed ID: 27941875
[TBL] [Abstract][Full Text] [Related]
18. Celiac anti-type 2 transglutaminase antibodies induce differential effects in fibroblasts from celiac disease patients and from healthy subjects.
Paolella G; Lepretti M; Barone MV; Nanayakkara M; Di Zenzo M; Sblattero D; Auricchio S; Esposito C; Caputo I
Amino Acids; 2017 Mar; 49(3):541-550. PubMed ID: 27613408
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase 2: a multi-functional protein in multiple subcellular compartments.
Park D; Choi SS; Ha KS
Amino Acids; 2010 Aug; 39(3):619-31. PubMed ID: 20148342
[TBL] [Abstract][Full Text] [Related]
20. Substrates, inhibitors, and probes of mammalian transglutaminase 2.
Zhuang R; Khosla C
Anal Biochem; 2020 Feb; 591():113560. PubMed ID: 31874171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
